Clinical Research Focus. 54th Edition

A Historic Milestone for Cell Therapy: The First CAR-T Approved for a Solid Tumor

A major milestone in oncology has been reached. China has approved the world’s first CAR-T therapy for a solid tumor, with CARsgen’s Claudin18.2-targeted treatment receiving authorization for gastric cancer. The approval marks a significant step forward for cell therapy, a field that has long struggled to replicate its success in blood cancers within solid tumors. Beyond the achievement itself, the decision highlights the growing role of China as a source of breakthrough oncology innovation and may signal the beginning of a new era for CAR-T development in solid tumors.

Learn more

ASCO 2026: Five Trends That Caught Our Attention

ASCO 2026 showcased far more than individual study results—it highlighted where oncology is heading next. From increasingly precise patient selection and the rise of ADCs and bispecific antibodies to China’s growing role in innovation, advances in cell therapy, and the emerging connection between metabolic health and cancer outcomes, several major trends stood out. In this article, Cromos Pharma CEO Vlad Bogin shares five key observations from ASCO 2026 and what they could mean for the future of oncology research and drug development.

Learn more

FDA Approves First Single-Dose Generic Treatment for Influenza

The FDA has approved the first generic version of baloxavir marboxil, the active ingredient in Xofluza, marking the first single-dose generic treatment for influenza. Approved for patients aged 5 years and older, the therapy can be used both to treat uncomplicated flu and to help prevent infection following exposure. Beyond expanding access to antiviral treatment ahead of the 2026–2027 flu season, the approval highlights the important role generic medicines play in improving affordability, adherence, and patient access to care.

Learn more

The Endpoint Bubble: Why Clinical Trials Are Drowning in Measurements That Don’t Matter

Clinical trial protocols are becoming increasingly crowded with biomarkers, imaging assessments, digital endpoints, patient-reported outcomes, and exploratory measures. While the goal is to maximize learning from every study, excessive endpoint expansion can increase complexity, burden patients and sites, and make results harder to interpret. In this article, Cromos Pharma CEO Vlad Bogin explores why endpoint discipline matters and how sponsors can focus on the measurements that truly support better development decisions.

Lean more

Can a Vaccine Help Prevent Fentanyl Overdose? A New Approach Shows Promise

A fentanyl vaccine has now entered human clinical testing, marking an important milestone in the fight against the opioid epidemic. Rather than treating addiction directly, the vaccine aims to generate antibodies that prevent fentanyl from reaching the brain, potentially reducing the risk of overdose. As noted in a recent JAMA editorial, it could become a valuable complement to existing treatment and harm-reduction strategies. Still early, but certainly a development worth watching.

Lear more

Can AI Decode Human Speech Directly from Brain Cells? New Research Brings the Possibility Closer

By combining single-cell brain recordings with advanced AI models, researchers have identified neuronal activity patterns that reflect the grammar, meaning, and context of spoken language. The study provides unprecedented insight into how individual neurons contribute to speech production and could help pave the way for future technologies that translate neural activity into speech for people with communication disorders. Beyond its clinical potential, the research offers a remarkable new window into the biological foundations of human language.

Learn more

New Lilly Data Show Promise for Fixed-Duration Treatment in CLL

New Phase 3 data presented at EHA 2026 reinforce the growing role of fixed-duration treatment strategies in chronic lymphocytic leukemia (CLL). In the BRUIN CLL-322 trial, adding Jaypirca (pirtobrutinib) to a time-limited regimen of venetoclax and rituximab significantly reduced the risk of disease progression or death, supporting a shift toward effective treatment approaches that may reduce the burden of continuous therapy.

Learn more

Operation Trailblazer: The US Pushes to Accelerate Clinical Trial Innovation

The U.S. Department of Health and Human Services has launched Operation Trailblazer, a new initiative aimed at strengthening America’s leadership in clinical research. By improving trial efficiency, expanding patient access, and reducing operational barriers, the program seeks to accelerate the development of innovative therapies and bring new treatments to patients faster.

Learn more